52 results about "Colorectal cancer cell line" patented technology

MicroRNAs (miRNAs) are a class of small noncoding RNAs that have important regulatory roles in multicellular organisms. The public miRNA database contains 321 human miRNA sequences, 234 of which have been experimentally verified. To explore the possibility that additional miRNAs are present in the human genome, we have developed an experimental approach called miRNA serial analysis of gene expression (miRAGE) and used it to perform the largest experimental analysis of human miRNAs to date. Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. The miRNAs are useful to diagnose and treat cancers.

The invention provides a colorectal carcinoma cell line CJF from hepatic metastasis and a construction method thereof. The obtaining method of the colorectal carcinoma cell line comprises the following steps: obtaining tissues of colorectal carcinoma hepatic metastasis; after digesting the tissues into single cells by using collagenase / hyaluronidase, separating and inoculating CD133+ cells under NOD (Non-Obese Diabetic) / SCID rat skin by MACS (magnetic-activated cell separation); nodulating, and taking out tumor tissues; and culturing in vitro to obtain the colorectal carcinoma cell line CJF which can stably passage and is rich in colorectal carcinoma stem cells. In the invention, CJF cells are obtained from hepatic metastasis of colonic carcinoma patients; compared with other colorectal carcinoma cell lines, the colorectal carcinoma cell line CJF has incomparable advantages for the study of the colonic carcinoma hepatic metastases; cell subsets of the CJF cells for stably expressing the CD133+ cells is about 10 percent; and the action and the research of the colorectal carcinoma cell line in a colorectal carcinoma hepatic metastases process and the tumor stem cells in a metastases mechanism have wide application prospects.

The invention belongs to the technical field of genetic engineering, and discloses long noncoding RNA SNHG15 and application thereof in preparation of cancer diagnosis and treatment drugs. Cancers include colorectal cancer, breast cancer, kidney cancer and the like. Expression of the long noncoding RNA SNHG15 in tumor tissues of patients suffering from the colorectal cancer, the breast cancer andthe kidney cancer is up-regulated. The patients with highly-expressed long noncoding RNA SNHG15 have poor prognosis. Through expression knock-down of the long noncoding RNA SNHG15 in colorectal cancercell lines, invasion, migration and multiplication capabilities of cells can be inhibited, and drug susceptibility of colorectal cancer cell lines to antitumor drugs including gemcitabine and cis-platinum can be improved.

The invention discloses a colorectal cancer stem cell vaccine preparation method and application. Postoperative tumor tissue cells derived from patients with colorectal cancer, human colorectal cancer cell lines Lovo or mouse colorectal cancer cell lines CT26 are prepared into CD133+ colorectal cancer stem cell vaccines by a repeated freezing-thawing method. The CD133+ colorectal cancer stem cell vaccines can reduce immunized mouse serum TGF-beta level, IFN-gamma level is improved, killing activity of NK (natural killer) cells and CDC (complement-dependent cytotoxicity) activity are enhanced, immunized mice resist colorectal cancer cell attack, immune cells are induced to selectively kill CD133+ colorectal cancer stem cells, and further tumor growth is inhibited.

The invention discloses a biphenyl compound serving as an antitumor medicament and a preparation method thereof. The biphenyl compound has antitumor activities in vitro and in vivo, has the effects of inducing apoptosis and inhibiting proliferation on colorectal cancer cell lines, lung cancer cell lines, liver cancer cell lines, breast cancer cell lines or pancreatic cancer cell lines in vitro and has the effects of inhibiting tumors on liver cancers and colorectal cancers in vivo. The biphenyl compound can be applied to preparation of the antitumor medicament. The preparation method of the biphenyl compound has the advantages of readily available raw materials, mild reaction conditions, easily operated reaction processes and cheap and readily available reagents.

The invention provides a fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from human rectal cancer tumor tissue. A classification name is Fusobacterium nucleatum subsp.animalis THCT5A4,a preservation number of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is CCTCC NO: M 2019366, the preservation date is May 17th, 2019,the preservation organization is China General Microbiological Culture Collection Center, and a 16SrRNA gene sequence of the fusobacterium nucleatum subsp.animalis strain THCT5A4 separated from the human rectal cancer tumor tissue is shown in SEQ ID NO:1 as shown in the description. A separation method of the fusobacterium nucleatum subsp.animalis strain is provided. A result of co-culture of a colorectal cancer cell line and the THCT5A4 shows that the THCT5A4 can significantly promote proliferation of colorectal cancer cells, therefore, the THCT5A4 can provide diverse in-vitro or in-vivo experimental conditions for simulating an intestinal environment for studies of colorectal cancer, and a colorectal cancer disease model can be built for screening medicines for treating colorectal cancer.

The invention provides a fusobacterium nucleatum polymorphic subspecies isolate THCT15E1, a classification name is Fusobacterium nuucleates subsp.nucleatum THCT15E1, a preservation number of the strain is CCTCC NO: M 2019362, a preservation date is May 17, 2019, a preservation unit is China Center for Type Culture Collection, and the 16SrRNA gene sequence of the strain is shown as SEQ ID NO: 1. The result of co-culture of the colorectal cancer cell line and THCT15E1 shows that THCT15E1 can significantly promote colorectal cancer cell proliferation; therefore, the THCT15E1 can provide diversified experimental conditions for in-vitro or in-vivo intestinal environment simulation for colorectal cancer research, and can also construct a colorectal cancer disease model to screen drugs for treating colorectal cancer.

The invention provides fusobacterium nucleatum THCT14E2 which is obtained from large intestine cancer tumor tissue and does not belong to known fusobacterium nucleatum subsp.vincentii. The 16SrRNA gene sequence of the strain is as shown in SEQID NO:1. The classification designation of the THCT14E2 is Fusobacterium nucleatum, the preservation number is CCTCC NO:M 2019361, the preservation date is May 17th, 2019, and the preservation unit is China Center for Type Culture Collection. The colorectal cancer cell line and THCT14E2 co-culture result shows that the THCT14E2 can significantly promote colorectal cancer cell proliferation. Therefore, the THCT14E2 can promote understanding of micro-ecology diversity of rectum cancer, and facilitate function research of the fusobacterium nucleatum fromthe colorectal cancer.

The present invention belongs to the field of medicine technology, and is especially one kind of medicine composition for regulating apparent genetic modification to prevent and treat gastrointestinal tumor. The medicine composition consists of effective components folic acid and sodium butyrate, medicine carrier and excipient. Experiments show that the medicine composition of the present invention can affect the methylation and acetylation of apparent genetic modification DNA, and further affect the gene expression of cell line of gastric cancer and / or large intestinal cancer or even change the cell period and inhibit tumor growth. The present invention has obvious tumor preventing and treating effect, no obvious toxic side effect and low cost.

The invention discloses a new use of ipomoea batatas Sporamin protein. According to the invention, ipomoea batatas Sporamin protein can be applied to prepare products for preventing and / or treating tumours and preparing inhibitors for the proliferation of eukaryote tumour cells. Tests of anticancer activity show that ipomoea batatas Sporamin protein is able to inhibit the proliferation and metastasis of SW480 and HCT-8 cells in human colorectal cancer cell lines and Lewis lung cancer cells, and also inhibit the invasion of the cells to a basement membrane. Thus ipomoea batatas Sporamin protein has an obvious anticancer effect. In addition, deriving from grain crop ipomoea batatas, ipomoea batatas Sporamin protein enjoys high security which ensures the long-term medication of patients. And having essential aminoacid that is reasonable in composition, ipomoea batatas Sporamin protein plays a role in nutrition improvement and can improve the health of cancer patients from multiple perspectives.

The present invention relates to the ferrocene derivative represented by formula (IA) or formula (IB), or to the pharmaceutically acceptable salt or solvate thereof and to the pharmaceutical composition thereof. Wherein, R is independently selected from H, halogen, cyano, nitro, C1-C6 alkyl, C1-C6 alkoxy, hydroxy-C1-C6 alkyl, halo-C1-C6 alkyl, halo-C1-C6 alkoxy or C1-C6 alkoxy-C1-C6 alkoxy; Z is selected from O, S or NR1, wherein R1 is independently H or C1-C6 alkyl; n is an integer from 0 to 5. The present invention also provides a method and the pharmaceutical application thereof for preparing the compounds represented by formula (IA) or formula (IB) or the pharmaceutically acceptable salts thereof. The compounds have a strong inhibitory activity against human lung cancer cell line A549, colorectal cancer cell line HCT116 and / or breast cancer cell line MCF-7.

A human-derived bradeion protein, which has the following properties: (i) it is a transmembranous protein; (ii) it has a structure characteristic of growth hormone and cytokine receptors even in a structure of its transmembranous portion when its structure is determined by a hydrophobicity analysis according to Kyte-Doolittle method; (iii) it is expressed at a high level in a human adult brain, and in less amount in the heart, while it is not expressed in other adult organs or fetus; (iv) it induces programmed cell death (apoptosis) when over-expressed in a cultured human nerve cell lines; (v) it induces termination of cell division and aging when over-expressed in a cultured human normal cell; (vi) it is located in cytoplasm, and forms an intracellular aggregate when overexpressed; and (vii) besides human adult neurons, it is specifically expressed in a human colorectal cancer cell line or in a skin cancer cell line, or an analogue thereof.

The invention relates to a nicotinic acid derivative shown in the formula (I), and pharmaceutically acceptable salt or solvate thereof, wherein Z is selected from O, S and NR3, and R3 is hydrogen or C1-6 alkyl; R1 or R2 is independently selected from hydrogen, C1-6 alkyl, C1-6 alkoxy group, halogenated C1-6 alkyl, halogen, nitro, aryl, aryl oxygroup, heteroaryl, heteroaryl oxygroup, heterocyclic radical, and heterocyclic oxygroup; C1-6 alkoxy group, halogenated C1-6 alkyl, aryl, heteroaryl, and heterocyclic radical can be optionally substituted by substituent groups which can be C1-6 alkyl, C1-6 alkoxy group, halogenated C1-6 alkyl, halogen, cycano, nitro and aryl; m is an integer of 0 to 4; and n is an integer of 0 to 5. The compound or salts thereof have strong inhibition activity to colorectal cancer cell line HCT-116, human lung cancer cell line A549 and breast cancer cell line MCF-7. In addition, the compound is broad-spectrum in anti-cancer activity, and can be used as a candidate drug or a pilot compound for treating diseases of tumors, cancers and the like.

The invention discloses a mutated ubiquitin specific protease 33 gene and application of the mutated ubiquitin specific protease 33 (USP33) gene to production of a medicine for treating colorectal cancer. A research finds out that KDM5B has high expression in a colorectal cancer clinical sample and a colorectal cancer cell line and promotes the proliferation of colorectal cancer cells through inhibiting USP33. A KDM5B inhibitor or a monoclonal antibody of the KDM5B can be used for remarkably inhibiting the proliferation of the colorectal cancer cells. A further research proves that the KDM5B is combined with a USP33 gene promotor region, and the inhibition of the expression to the USP33 gene is realized through combining an upstream specific regulation and control sequence GCACA / C or G / TGTGC. The mutated ubiquitin specific protease 33 gene obtained through a site-directed mutation PCR (Polymerase Chain Reaction) technology can be used for resisting the inhibition effect of the KDM58B, so that the growth of the colorectal cancer cell line is inhibited.

The invention provides mutain of a human insulin-like growth factor conjugated protein 7 (IGFBP7). The mutain contains mutation of Arg198Ile / His200Phe, and has an amino acid sequence of SEQ ID NO.1. An igfbp7 gene coding sequence is selected from an SW480cDNA library of a human colorectal cancer cell line and is constructed into pET28a plasmids of a prokaryotic expression vector, so that the IGFBP7 protein can be expressed in a colon bacillus strain BL21. On the basis of the expression vector, mutain of the IGFBP7 is constructed, BL21 is converted, the mutain is expressed and purified, and a key site where the IGFBP7 is bonded with insulin is pointed out. The mutain provided by the invention has simple steps in a preparation method and high success rate, and the bonding capacity of the protein with insulin is remarkably reduced, so that insulin resistance can be suppressed and the mutain can be applied to the preparation of a medicament for treating type 2 diabetes.

The invention discloses a human colorectal cancer cetuximab drug-resistant cell line, and belongs to the field of biomedical technology. The human colorectal cancer cetuximab drug-resistant cell linehas the advantages that a human colorectal cancer cell line NCI-H508 is treated by the cetuximab of different concentration, and the drug concentration for survival of 50% of cells is used as the initial concentration to treat the cells for a long time, until the cell NCI-H508 can normally grow under the concentration; the cell NCI-H508 is continued to treat for a long time by a gradual increasingmethod, the treatment duration is six months, and finally the human colorectal cancer cetuximab drug-resistant cell line NCI-H508 / C225 which can quickly grow under the treatment function of the cetuximab can be finally obtained; the human colorectal cancer cetuximab drug-resistant cell line can be used for analyzing the phenotypic change of morphology and biology after drug resistance of human colorectal cancer cetuximab, studying the molecule mechanism of the human colorectal cancer cetuximab drug resistance and the reversing drug resistance method, screening other anti-tumor drugs, findingthe tumor drug-resistant markers, and screening and evaluating the novel antitumor drugs and the like, and the scientific and research value and the production and application value are higher.

The invention relates to an application of a natural compound 3-deoxysappanchalcone (3-DSC for short) in preparing medicine for inhibiting tumor cell proliferation. According to a cell proliferation experiment, the inhibiting effect of 3-DSC in a colorectal cancer cell line, especially in four cell lines: HCT-15, HCT-116, SW620 and DLD1 with highly expressed TOPK, is verified, therefore providing help and ground for clinically researching medicine for preventing and treating colorectal cancer.

The invention provides an application of a compound DY1 in preparation of anti-colorectal cancer drugs. According to conventional literature reports, a colorectal cancer surface molecule CD58 newly discovered is researched; a small-molecular compound specifically binding to the CD58 is selected for further drug research; a targeting small-molecular drug originated from natural products is obtained through a computer-aided drug screening technology; cell biology experimental results indicate that the natural product DY1 has significantly inhibiting effect on growth of an SW620 human colorectal cancer cell line, has the IC50 value of 31.30+ / -0.88 [mu]mol, and can be further used for development of new drugs for treatment of colorectal cancer.

MicroRNAs (miRNAs) are a class of small noncoding RNAs that have important regulatory roles in multicellular organisms. The public miRNA database contains 321 human miRNA sequences, 234 of which have been experimentally verified. To explore the possibility that additional miRNAs are present in the human genome, we have developed an experimental approach called miRNA serial analysis of gene expression (miRAGE) and used it to perform the largest experimental analysis of human miRNAs to date. Sequence analysis of 273,966 small RNA tags from human colorectal cells allowed us to identify 200 known mature miRNAs, 133 novel miRNA candidates, and 112 previously uncharacterized miRNA* forms. To aid in the evaluation of candidate miRNAs, we disrupted the Dicer locus in three human colorectal cancer cell lines and examined known and novel miRNAs in these cells. The miRNAs are useful to diagnose and treat cancers.

The invention provides a method for establishing a colorectal cancer animal model with an inflammation basis. The method includes the following steps that firstly, pBabe-CMV-EGFP-puro plasmids are established; secondly, a retrovirus-mediated EGFP overexpression system is established; thirdly, a colorectal cancer cell line stably expressing EGFP is established; fourthly, an axillary colorectal cancer transplanted tumor model of group A nude mice is established; fifthly, an inflammation model of group B nude mice is established; sixthly, the colorectal cancer animal model with the inflammation basis is established, wherein an axillary tumor of the group A nude mice is excised and sheared into tumor blocks with the diameter of 2 mm or so through sterile eye scissors, one tumor block is taken and directly sewn to the wall of the colorectum of the group B nude mice, the fifth step is repeated, feeding is carried out for one week, the fifth step is repeated again, feeding continues for one week, and the cancer animal model is obtained. With the animal model established through the method, the existence of tumors can be verified, and the size of tumors can be estimated.

The invention provides an application of a small molecule inhibitor minoxidil of PLOD2 in tumor treatment, and the chemical name of the minoxidil is 6-(1-piperidyl)-2, 4-pyrimidinediamine, 3-oxide. The invention specifically relates to a second indication of a small molecule inhibitor minoxidil, namely a therapeutic effect on colorectal cancer by inhibiting PLOD2. According to the method, firstly,proteomics comparison is used for determining the colorectal cancer high-expression protein PLOD2; after partial knockout of a basic group encoding PLOD2, the proliferation, migration and invasion capabilities of colorectal cancer cells are reduced, and the possibility that PLOD2 is used as a colorectal cancer treatment target is proposed. An inhibitor minoxidil of PLOD2 protein is used for inhibiting PLOD2 in a colorectal cancer cell line, the malignant ability of tumor cells is reduced, and it is verified on a mouse model that minoxidil can inhibit growth of intestinal cancer xenograft tumors with high expression of PLOD2.

The invention provides application of a KPNA2 (karyopherin alpha 2) gene and application of siRNA (small interfering ribonucleic acid) for inhibiting expression of the KPNA2 gene, and relates to the technical field of medicine gene engineering. The application of the KPNA2 gene as a colorectal cancer biomarker provided by the invention can be used for effectively instructing the clinical stages of the colorectal cancer, and accurately judging the prognosis of a colorectal cancer patient. The siRNA for inhibiting the expression of the KPNA2 gene can effectively inhibit the proliferation and transfer of colorectal cancer cells. The invention also provides application of the siRNA in preparing a KPNA2 gene silent colorectal cancer cell line. The cell line can be used for studying the correlation and mechanism between KPNA2 and the colorectal cancer, and providing a reliable study foundation for deeply studying the possible mechanism of generation and development between the KPNA2 and the colorectal cancer, thereby providing an effective therapeutic target for the target therapy of the colorectal cancer.

The invention discloses a method for establishing an HK2 report gene cell line of the colon cancer. The method comprises the specific steps of firstly designing a specificity sgRNA sequence of a HK2 gene site, and performing cloning into a plasmid PX459; integrating a homologous recombination sequence of an HK2 gene and a green fluorescent protein DNA fragment (EGFP), and performing joint electricshock on the plasmid and the integrated fragment to transform a colon cancer cell line HCT116; performing unicellular screening on EGFP expression cells through a flow cytometer, and amplifying a monoclonal cell line; and performing PCR identification and immunoblotting verification on the screened EGFP expression cell line so as to obtain a positive HK2 report gene cell line. The colon cancer cell line cell line HK2 gene and EGFP are in co-expression, and the EGFP expression level and the HK2 gene have high consistency, so that through detecting EGFP expression level changes, the HK2 gene expression level can be accurately judged. The method for establishing the cell line is simple, and easy to operate, and gene sites can be efficiently and accurately positioned.

The invention relates to a method for domesticating and culturing a colorectal cancer cell line through an organoid, which comprises the following steps of performing domestication culture on colorectal cancer single cells in colorectal cancer organoids for multiple times by using an organoid carrier and a domestication culture medium, and gradually reducing the use amount of the organoid carrier in the domestication culture process, such that the colorectal cancer single cells in colorectal cancer organs gradually adapt to a two-dimensional culture environment and are finally domesticated into an immortalized colorectal cancer cell line. The invention creatively provides a brand-new method for domesticating and culturing the colorectal cancer cell line through organoids, the method can remarkably shorten the line building time of the colorectal cancer cell line, and the line building success rate of the colorectal cancer cell line is increased; in addition, the method is simple in culturing condition and easy to implement, and the human-derived colorectal cancer cell line can be efficiently established from the primary cells in vitro at low cost.

The invention discloses a new use of ipomoea batatas Sporamin protein. According to the invention, ipomoea batatas Sporamin protein can be applied to prepare products for preventing and / or treating tumours and preparing inhibitors for the proliferation of eukaryote tumour cells. Tests of anticancer activity show that ipomoea batatas Sporamin protein is able to inhibit the proliferation and metastasis of SW480 and HCT-8 cells in human colorectal cancer cell lines and Lewis lung cancer cells, and also inhibit the invasion of the cells to a basement membrane. Thus ipomoea batatas Sporamin protein has an obvious anticancer effect. In addition, deriving from grain crop ipomoea batatas, ipomoea batatas Sporamin protein enjoys high security which ensures the long-term medication of patients. And having essential aminoacid that is reasonable in composition, ipomoea batatas Sporamin protein plays a role in nutrition improvement and can improve the health of cancer patients from multiple perspectives.